Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: John R Resseger who wrote (2862)	1/10/1999 1:03:00 PM
From: CAP	Read Replies (1) \| Respond to of 3725

All, Had dinner with a friend last night who recently had a Heartscan at the Washington DC site. He was on a commercial aircraft flight and had chest pain, jaw pain and pain down his left arm.... yikes! The guy is a dentist and immediately suspected the worst. Turned out for him that it was a GI thing that gave the symptoms of a heart attack warning. His wife had heard the ads for the Heartscan and made an appointment (he didn't wwant to go) and directed him to keep it. He was amazed at the procedure, got a good scan and clean bill of health. Said they had appointments lined up every 20 mins @ $550 a pop and folks kept rolling in the door. I have watched IMAT for 5 years now, had and sold a position 3 years ago, and am going to get back in. I think it is time for IMAT... not just because of my friend's experience but because of the mountain of evidence that has built up as to its capability and the crushing weight of need for preventative medicine in our aging population. The recent articles indicating potential savings for emergency room care and allowing certain screening for those who really don't have heart problems add to the mix. With GE involved and with the previously mentioned items in mind, I believe we are months away from a broadly recognized appreciation of the tech and a resultant desire of folks to get some of "that stock." Since IMAT is not mentioned in these articles by name, the company is at this point "unknown." As soon as it emerges from "behind the curtain," I think there will be a stampede. That said, I am also well aware of the tremendous amount of stock the company has outstanding (77m shares in the float 89m issued) is not very appealing. However, as I also understand it, the company has no long term debt. Thoughts and comments would be welcomed. All the best, CAP